Zobrazeno 1 - 3
of 3
pro vyhledávání: '"T. Prasad Sahoo"'
Autor:
D. Lokanatha, Minish Mahendra Jain, Virginia G. Kaklamani, Lee S. Schwartzberg, Wj. Gradishar, Shailesh Arjun Bondarde, Vinod Raina, T. Prasad Sahoo
Publikováno v:
Cancer Research. 70:P2-16
Background: Sorafenib (SOR) is an oral multikinase inhibitor that targets tumor growth and angiogenesis. We previously reported progression-free survival (PFS) data from the primary analysis of NU07B1 (SABCS 2009 abstr 44), a phase 2b trial assessing
Autor:
T. Prasad Sahoo, Carla Visseren-Grul, Annamaria Zimmermann, Olivier Molinier, C. Gridelli, E. Laack, F. De Marinis, William J. John, Luis Paz-Ares, Martin Reck
Publikováno v:
Annals of Oncology. 23:ix404
Background PARAMOUNT demonstrated that pem continuation maintenance significantly reduced the risk of disease progression (HR = 0.62) and death (HR = 0.78) versus plb in patients (pts) with advanced NS NSCLC. Preplanned subgroup analyses by baseline
Autor:
Shailesh Arjun Bondarde, D. Lokanatha, Minish Mahendra Jain, T. Prasad Sahoo, William J. Gradishar, Virginia G. Kaklamani, Vinod Raina
Publikováno v:
Cancer Research. 69:44-44
Introduction: SOR is a targeted therapeutic agent indicated for advanced renal cell carcinoma and hepatocellular carcinoma. SOR targets multiple kinases involved in tumor growth and angiogenesis. The TIES (Trials to Investigate the Effects of Sorafen